Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients

June 22, 2020

Study Background

Programmed death ligand 1 (PD-L1) is a biomarker associated with response to programmed death-1 (PD-1) and PD-L1 immune checkpoint inhibitors1\r\n\u2022 Four immunohistochemistry (IHC) assays for PD-L1 expression have been approved\r\nacross a number of tumor types\r\n\u2022 Manual assessment of PD-L1 expression is limited by variability in assay and scoring methodology, heterogeneous tumor PD-L1 expression, and interobserver variability\r\n\u2014 Interpathologist discordance may increase for tumor samples with low\r\nexpression of PD-L1\r\n\r\n\u2022 Digital quantification may improve the precision of PD-L1 assessment by\r\novercoming certain limitations observed with manual scoring, as suggested in various tumor types, including non-small cell lung cancer, melanoma (MEL), and urothelial carcinoma (UC)

View Poster

Get In Touch

PathAI Media

Company Contact

Liz Storti

Chief People Officer

elizabeth.storti@pathai.com

Media Contact

Daniel Donato

LifeSci Communications

ddonato@lifescicomms.com

516-474-0554